(24/7 MARKET NEWS) – Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is trading higher on news that Astellas, a Tokyo listed company, plans to invest a total of $50 million to acquire 15% of Taysha Gene to support the development of Taysha’s AAV-based Gene Therapy Programs and receive an exclusive option to obtain an exclusive license for TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN).
Taysha Gene Therapies is trading at $2.03, 52 cents higher (+34.44%), on 1.4 million shares.
Its 52-week range is $1.35 to $17.10, with the $2.25 level looking like a key inflection point, if it can break through that resistance, it can begin to challenge weaker resistance points to the $3 level. It also has the feel of one that could pullback before the regular session open and then resume the move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.